Tags

Type your tag names separated by a space and hit enter

[Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Dtsch Med Wochenschr. 2020 05; 145(10):682-686.DM

Abstract

Twenty years ago, an enzyme homologous to the previously known angiotensin-converting enzyme (ACE) was identified, and subsequently named ACE2. In the renin-angiotensin system (RAS), ACE2 has counter-regulatory functions against the classical effector peptide angiotensin II, for example in blood pressure regulation and cardiovascular remodeling. However, ACE2 provides an initially unexpected interesting link between virology and cardiovascular medicine. That is, ACE2 represents the binding receptor for the cellular uptake of SARS-CoV and SARS-CoV-2 viruses. Thus, ACE2 is relevant for COVID-19. In this context, it was suspected that therapy with RAS blockers might promote transmission and complications of COVID-19 by upregulation of ACE2 expression. The aim of this short review is, to describe the link between the RAS, particularly ACE2, and COVID-19. Based on our analysis and evaluation of the available findings, we justify our conclusion: important drugs such as ACE inhibitors and angiotensin receptor blockers should continue to be prescribed according to guidelines to stable patients in the context of the COVID-19 pandemic.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

ger

PubMed ID

32323279

Citation

Kreutz, Reinhold, et al. "[Renin-Angiotensin-System (RAS) and COVID-19 - On the Prescription of RAS Blockers]." Deutsche Medizinische Wochenschrift (1946), vol. 145, no. 10, 2020, pp. 682-686.
Kreutz R, Abd El-Hady Algharably E, Ganten D, et al. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. Dtsch Med Wochenschr. 2020;145(10):682-686.
Kreutz, R., Abd El-Hady Algharably, E., Ganten, D., & Messerli, F. (2020). [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. Deutsche Medizinische Wochenschrift (1946), 145(10), 682-686. https://doi.org/10.1055/a-1152-3469
Kreutz R, et al. [Renin-Angiotensin-System (RAS) and COVID-19 - On the Prescription of RAS Blockers]. Dtsch Med Wochenschr. 2020;145(10):682-686. PubMed PMID: 32323279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. AU - Kreutz,Reinhold, AU - Abd El-Hady Algharably,Engi, AU - Ganten,Detlev, AU - Messerli,Franz, Y1 - 2020/04/22/ PY - 2020/4/24/pubmed PY - 2020/5/23/medline PY - 2020/4/24/entrez SP - 682 EP - 686 JF - Deutsche medizinische Wochenschrift (1946) JO - Dtsch. Med. Wochenschr. VL - 145 IS - 10 N2 - Twenty years ago, an enzyme homologous to the previously known angiotensin-converting enzyme (ACE) was identified, and subsequently named ACE2. In the renin-angiotensin system (RAS), ACE2 has counter-regulatory functions against the classical effector peptide angiotensin II, for example in blood pressure regulation and cardiovascular remodeling. However, ACE2 provides an initially unexpected interesting link between virology and cardiovascular medicine. That is, ACE2 represents the binding receptor for the cellular uptake of SARS-CoV and SARS-CoV-2 viruses. Thus, ACE2 is relevant for COVID-19. In this context, it was suspected that therapy with RAS blockers might promote transmission and complications of COVID-19 by upregulation of ACE2 expression. The aim of this short review is, to describe the link between the RAS, particularly ACE2, and COVID-19. Based on our analysis and evaluation of the available findings, we justify our conclusion: important drugs such as ACE inhibitors and angiotensin receptor blockers should continue to be prescribed according to guidelines to stable patients in the context of the COVID-19 pandemic. SN - 1439-4413 UR - https://www.unboundmedicine.com/medline/citation/32323279/[Renin_Angiotensin_System__RAS__and_COVID_19___On_The_Prescription_of_RAS_Blockers]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/a-1152-3469 DB - PRIME DP - Unbound Medicine ER -